Mitazalimab

LUND, SE / ACCESS Newswire / July 2, 2026 / Alligator Bioscience (STO:ATORX) First patient dosed in an investigator-initiated trial evaluating intratumoral mitazalimab, with or without intratumoral nivolumab Study evaluates how local CD40 activation affects the tumor microenvironment ahead of surgery to inform future clinical development Trial conducted at an Ivy League university in the United States Lund, Sweden - 2 July 2026 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that the first patient has been dosed in an investigator-initiated trial (IIT, NCT07319195 ) evaluating intratumoral administration of mitazalimab, Alligator's lead CD40 agonist, in patients with early-stage breast cancer. The study will evaluate mitazalimab given as a single intratumoral dose, either alone or in combination with a single intratumoral dose of the PD-1 inhibitor nivolumab, prior to surgery. While checkpoint inhibitors have improved outcomes in some breast cancer subtypes, there remains a need for more effective and better-tolerated immunotherapy approaches in others. In a recent publication in NPJ Breast Cancer , Dr Zhang has demonstrated that CD40 agonists synergize with PD-1 inhibitor in preclinical breast cancer models eradicating tumors and providing long lasting tumor immunity. This IIT will explore if local CD40 activation can enhance anti-tumor immunity in resectable breast cancer, and generate translational insights to guide further randomized trials. The primary endpoints are safety and feasibility of administering mitazalimab, with or without nivolumab, prior to surgery. Secondary and exploratory objectives include pathologic and imaging-based measures of anti-tumor activity and translational analyses intended to characterize immune activation in the tumor microenvironment. "We are pleased to support this investigator-initiated trial evaluating intratumoral mitazalimab in early-stage breast cancer. Breast cancer is the most common cancer in women, and the leading cause of cancer-related death. said Søren Bregenholt, CEO of Alligator Bioscience . As the biology and treatment of breast cancer varies significantly from that of pancreatic cancer this trial has the potential to generate valuable new translational insights that can guide future development to expand the clinical utility of mitazalimab." About investigator-initiated trials Investigator-initiated trials (IITs) are sponsored and executed by clinical investigators, with Alligator's consent, but without our direct involvement besides supplying mitazalimab, providing scientific input and ensuring certain aspects of clinical safety reporting. IITs offer the opportunity to strengthen our understanding of mitazalimab's mechanism of action, expand its potential use beyond pancreatic cancer, and explore additional indications to support further development. Alligator announces the initiation of an IIT once the first patient has been dosed with mitazalimab, and shares key outcomes and milestones, but does not commit to provide regular updates on individual trials. For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 10:30 a.m. CEST on 2 July 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

LUND, SE / ACCESS Newswire / June 8, 2026 / Alligator Bioscience (STO:ATORX) today comments on a recent update regarding patient recruitment in the ongoing Phase 3 clinical trial of HLX22, developed by Shanghai Henlius Biotech, Inc. According to communication shared by Henlius, the first patients have now been dosed in all regions participating in the global Phase 3 study of HLX22, including China, Japan, Korea, Latin America, Australia, the United States and Europe. HLX22 is an innovative anti-HER2 monoclonal antibody that has been granted orphan drug designation in both the U.S. and EU for gastric cancer and is being developed by Henlius under a license from AbClon, Inc., following a discovery collaboration which grants Alligator the right to participate in potential future revenues. "The successful dosing of the first patients across all regions marks an important milestone, signaling the continued progress in the Phase 3 study with HLX22," said Søren Bregenholt, CEO of Alligator Bioscience . "The continued advancement also suggests sustained investigator interest in evaluating HLX22 as a potential treatment option for patients with gastric cancers." Under the terms of Alligator's agreement with AbClon, Alligator is entitled to 35% of AbClon's revenue from its sublicense to Henlius, including potential milestone payments and royalty revenues, which, if HLX22 is successfully developed and approved, could represent a meaningful long-term revenue opportunity for Alligator. For further information, please contact: Søren Bregenholt, CEO E-mail: soren.bregenholt@alligatorbioscience.com Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 08:45 a.m. CEST on 8 June 2026. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 30-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire